Revelation Biosciences REVB
NASDAQ REVB
$3.62 -0.13 (-3.47%)
As of: Oct 21, 2026 · 3:59 PM EDT

Revelation Biosciences (REVB) Net Margin (2025 - 2026)

Updated

Analysis

Revelation Biosciences (REVB) Net Margin (2025 - 2026) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Margin (Qtr)
1 Eli Lilly 1,136.97 Bn 1,105.55 Bn 19.71 Bn 30.88%
2 Johnson & Johnson 619.72 Bn 538.25 Bn 17.26 Bn 21.86%
3 AbbVie 503.40 Bn 476.52 Bn 12.70 Bn 21.27%
4 Merck 370.15 Bn 324.53 Bn 12.21 Bn -8.04%
5 Novartis Ag 298.64 Bn 262.63 Bn 11.24 Bn 22.65%
6 Astrazeneca 261.07 Bn 234.76 Bn 12.86 Bn 16.30%
7 Amgen 237.00 Bn 192.40 Bn 7.24 Bn 23.62%
8 Gilead Sciences 191.24 Bn 165.43 Bn 6.22 Bn -134.51%
9 Pfizer 170.31 Bn 116.96 Bn 10.94 Bn -1.65%
10 Revelation Biosciences 13.82 Mn -35.20 Mn - -4,045.06%
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -4,045.06%
Jun 30, 2025 -28,599.88%
API Access

Revelation Biosciences Net Margin API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=net-margin&ticker=REVB&period=max&api_key=YOUR_API_KEY